Position in DRTS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,035,019
+$415,453 QoQ
Shares Held
146,396
+17.0% QoQ
Ownership
0.162%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DRTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Mariner, LLC holds $323,759,564 across 135 Biotechnology names. DRTS ranks #27 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
123,954 | $95,771,817 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131,600 | $58,764,661 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
557,361 | $29,384,071 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
268,901 | $15,190,217 | |
| 5 | EXEL |
Exelixis, Inc.
|
307,928 | $13,207,031 | |
| 6 | INCY |
Incyte Corp
|
121,091 | $11,397,084 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
29,948 | $9,908,894 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
40,016 | $7,565,024 |
All Filings in DRTS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,035,019 | 146,396 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $619,566 | 125,165 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $555,857 | 123,250 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $134,537 | 43,121 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $100,703 | 40,121 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $126,328 | 40,751 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $96,987 | 40,751 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $105,991 | 41,894 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $113,822 | 38,584 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $116,137 | 38,584 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||